NORA BARRY FISCHER, District Judge.
A number of motions are currently pending before the Court in this case. (See Docket Nos. 352, 356, 360, 364, 367, 370, 373). This opinion addresses two of the pending motions because they raise similar issues. The first is the Defendants' (collectively, "Marvell") "Motion for Partial Summary Judgment of No Infringement and No Damages with Respect to Extraterritorial Conduct." (Docket No. 356). In that motion, Marvell requests that this Court determine that it (Marvell) cannot be found liable for infringement of any methods claimed in U.S. Patent Nos. 6,201,839 ("the `839 Patent") or 6,438,180 ("the `180 Patent") (collectively, "the CMU Patents") for chips that are never used in the United States, and that Plaintiff
The second motion is similar. In that motion, Marvell requests that the Court find that it (Marvell) cannot be found liable for infringement for the use of the patented technology by non-party Seagate Technology. (See Docket No. 360). As with the extraterritorial conduct motion, Marvell also requests that this Court find that it (Marvell) cannot be liable for damages arising from its sales to Seagate. (Id.). As expected, CMU challenges this proposition. (See Docket Nos. 397, 430).
After consideration of the parties' arguments and the filings pertaining to these motions, the Court has determined that both motions (Docket Nos. 356, 360) should be granted, in part, and denied, in part, in accordance with the following.
Much of the factual background of this case has been discussed elsewhere (see Docket Nos. 306, 227), so the Court only addresses here the facts pertinent to the pending motions. The instant motions pertain to Marvell's international activities and its sales to Seagate, so the Court will recount only the facts relevant to those issues.
Marvell produces read channel chips
At the beginning of Marvell's sales cycle, the company formulates the product's concept and basic design. As Marvell performs the necessary research and development, it uses simulators ("Simulation Programs")
Once a given Simulation Program performs satisfactorily, Marvell sends the specifications to an offshore manufacturer, who then produces engineering samples for Marvell. (Id. at ¶ 26). Marvell and its customers then test the engineering samples, which are Accused Chips, in the United States. (Id. at ¶¶ 30, 31, 34). Marvell's customers must sign off on the qualification of the test samples of the Accused Chips before full production begins. (Id. at ¶ 35). Marvell retains "golden unit" chips in California for each Accused Chip that is developed. (Id. at ¶ 36-37). These golden unit chips are used to test failed production versions of the Accused Chips. (Id. at ¶ 38). After a design is settled upon, Marvell provides "tuning guides," "reference settings," and "Application Notes" to help customers use the Accused Chips. (Id. at ¶¶ 44-47).
It is undisputed that, between March 6, 2003 and March 31, 2010, Marvell sold 1,469,070,073
The parties dispute the actual location of the sales of the Accused Chips. (Docket No. 440 at 7). CMU's position is that these sales occurred within the United States, and for purposes of the pending motion, Marvell has assumed that the relevant sales do actually take place in the United States. (Id.). Thus, for purposes of the analysis that follows, the Court will assume that Marvell's sales relating to the alleged infringements occur within the United States.
The parties are in agreement that Seagate and CMU have had an ongoing relationship since the early 1990s. Although there is some dispute as to the details, the parties agree that, beginning on October 1, 1992, Seagate entered into an "Associate Agreement"
The Associate Agreement provided Seagate with, among other things, "a worldwide, irrevocable, royalty-free license, to make, have made for their own use, or sell the product of the Inventions." (Docket No. 398 at ¶ 11). The Agreement also required CMU to charge royalty-bearing licenses to third parties who sought licenses for DSSC technologies. (Id.). Marvell does not have a license to use the CMU Patents. (Id. at ¶ 16).
There is nothing in the record evidence to indicate that Marvell's sales cycle with Seagate proceeded differently from the standard procedure described above. Hence, it would appear that Marvell did not legally consummate its relationship with Seagate until after all of the design testing described above. Further, there is no indication in the evidence presently before this Court that Seagate instructed Marvell to design the Accused Chips that Marvell eventually sold to Seagate. (Docket No. 398 at ¶ 25-26).
"The court shall grant summary judgment if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law." FED.R.CIV.P. 56(a). Pursuant to Rule 56, a district court must enter summary judgment against a party "who fails to make a showing sufficient to establish the existence of an element essential to that party's case, and on which that party will bear the burden of proof at trial." Celotex Corp. v. Catrett, 477 U.S. 317, 322, 106 S.Ct. 2548, 91 L.Ed.2d 265 (1986). "Only disputes over facts that might affect the outcome of the suit under the governing law will properly preclude the entry of summary judgment." Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248, 106 S.Ct. 2505, 91 L.Ed.2d 202 (1986).
Summary judgment may be granted when no "reasonable jury could return a verdict for the nonmoving party." Id. Therefore, in performing its analysis, a court should "view the evidence in a light most favorable to the opposing party and resolve doubts in its favor." Ethicon Endo-Surgery, Inc. v. U.S. Surgical Corp., 149 F.3d 1309, 1315 (Fed.Cir.1998).
When a non-moving party would have the burden of proof at trial, as is the case here, the moving party has no burden to negate the opponent's claim. Celotex, 477 U.S. at 323, 106 S.Ct. 2548. Thus, the moving party does not need to produce any evidence showing the absence of a genuine issue of material fact. Id. at 325, 106 S.Ct. 2548. "Instead, ... the burden on the moving party may be discharged by `showing' — that is, pointing out to the district court — that there is an absence of evidence to support the nonmoving party's case." Id. After the moving party has satisfied this low burden, the adverse party must provide facts showing that there is a genuine issue for trial in order to counter the motion for summary judgment. Id. at 324, 106 S.Ct. 2548.
CMU's infringement theories arise under 35 U.S.C. §§ 271(a), (b) and (c). (Docket No. 401 at 5). This means that they encompass both direct and indirect
Direct infringement of a U.S. patent occurs when a party, "without authority makes, uses, offers to sell, or sells any patented invention, within the United States." 35 U.S.C. § 271(a) (emphasis added). Method claims are not infringed simply by the sale of an apparatus that is capable of infringing use. Ormco Corp. v. Align Tech., Inc., 463 F.3d 1299, 1311 (Fed.Cir.2006); Standard Havens Products, Inc. v. Gencor Industries, Inc., 953 F.2d 1360, 1374 (Fed.Cir.1991). "Because a process is nothing more than the sequence of actions of which it is comprised, the use of a process necessarily involves doing or performing each of the steps recited." NTP, Inc. v. Research in Motion, Ltd., 418 F.3d 1282, 1318 (Fed.Cir.2005). Thus, direct infringement of a method claim only occurs if each step of the claimed method is actually performed. See Muniauction, Inc. v. Thomson Corp., 532 F.3d 1318, 1328 (Fed.Cir.2008); see also Ricoh Co., Ltd. v. Quanta Computer Inc., 550 F.3d 1325, 1333 (Fed.Cir.2008) (citing BMC Resources, Inc. v. Paymentech, L.P., 498 F.3d 1373, 1378-79 (Fed.Cir.2007)).
There are also two forms of indirect infringement: inducing infringement and contributory infringement. These modes of infringement are governed by 35 U.S.C. § 271(b)
Patent damages are governed by 35 U.S.C. § 284
As described above, direct infringement of a method patent requires a showing that all of the claimed steps are performed. NTP, 418 F.3d at 1318. Moreover, a sale of an apparatus capable of performing the method is not sufficient to prove infringement. Ormco, 463 F.3d at 1311. Thus, with respect to the question of infringement, the location of Marvell's sales is irrelevant because such sales, at any location, are insufficient to make a showing of infringement.
Although Marvell's conduct cannot be considered directly infringing, Marvell may still be liable for indirect infringement because some of the chips that are sold abroad do eventually make their way to the United States. (See Docket No. 402 at ¶¶ 42-43). Marvell's motion does not appear to assert non-infringement on this basis, and indeed, at oral argument, Marvell's attorney implicitly acknowledged that Marvell could be liable for indirect infringement based on those imported chips. (See
With respect to infringement, Marvell's licensed use motion is entirely correct, and the Court will grant summary judgment of non-infringement "with respect to licensed use of the patented technology by non-party Seagate Technology." (See Docket No. 360 at 1) (emphasis added). The license clearly grants Seagate, as an Associate Member of the DSSC, "a worldwide, irrevocable, royalty-free license to make, have made for [its] own use, or sell" the patented method. (Docket No. 398 at ¶ 11). This language makes clear that Seagate's own use is not infringing, which in turn means that Marvell cannot be indirectly liable for infringement. Thus, summary judgment is appropriate as to any use by Seagate.
Seagate's use, however, is not really what is at issue in this case. The true question lies with Marvell's use during the sales cycles in which it produced chips for Seagate. That question is more complicated, but in the end, must be found against
The only potential means for Marvell to protect itself from infringement under the Associate Agreement is to show that its use was an exercise of Seagate's "have made" rights. Based on the structure of the sales cycle, Marvell's conduct during the period in which Seagate was "shopping" for chips, prior to an actual design win by Marvell, does not qualify as an exercise of Seagate's "have made" rights. "The legal effect of licensees exercising their `have made' rights by commissioning a third party to make licensed products is very different from the legal effect of licensees purchasing allegedly infringing products from a third party." Intel Corp. v. Broadcom Corp., 173 F.Supp.2d 201, 234 (D.Del.2001). Where a licensee commissions the work, a third party's acts do not infringe. Id. When there is no agreement between the licensee and the third party, the third party's acts do infringe. Id. A third party "cannot unilaterally rely on the rights of the licensees who purchase its products, when none of those licensees' rights have been conferred" upon the third party. Id.
The evidence of record indicates that Marvell uses the methods at issue during its sales cycle, but this evidence is devoid of any specific agreement between Marvell and Seagate prior to Marvell's design win. Thus, Marvell's use — prior to achieving a design win — must be considered infringing, even if that use eventually led to noninfringing sales to Seagate.
All told, the Court finds it appropriate to grant summary judgment of non-infringement to Marvell in connection with sales of chips that are never used in the United States and for use of the patented technology by Seagate Technology.
In conjunction with its motions for non-infringement, Marvell also asserts that it is not liable for damages arising from the same activities outlined above. (See Docket Nos. 356, 360). Although the Court found that Marvell's motions should be granted as to non-infringement, the Court will not grant the damages portions of either motion for the following reasons.
In the Court's view, the analysis for both motions is essentially the same. Recalling that Marvell's burden is "`showing' — that is, pointing out to the district court — that there is an absence of evidence to support the nonmoving party's case," Celotex, 477 U.S. at 325, 106 S.Ct. 2548, this Court finds that Marvell has failed to meet this burden.
Generally put, Marvell's position is that because its sales — whether to Seagate or of the extraterritorial variety — are non-infringing, CMU may not recover damages based on those sales. In both motions, Marvell relies heavily on Mirror Worlds, LLC v. Apple, Inc., 784 F.Supp.2d 703 (E.D.Tex.2011). Marvell's reliance on a readily-distinguishable district court case that has not been reviewed by the Federal Circuit does not meet this burden.
The facts of record — construed in a light most favorable to CMU — show that Marvell infringes the CMU Patents throughout the sales cycle. The facts indicate, and Marvell evidently admits, that Marvell uses the infringing Simulation Programs and Accused Chips throughout its sales cycle. See supra, Part II.a. CMU asserts, and Marvell does not deny, that "Marvell
Marvell argues that this Court should follow the holding in Mirror Worlds that "because [defendant's] sales or offers for sale do not infringe the asserted method patents, they cannot be the basis for damages." (Docket No. 357 at 5). The Court does not read Mirror Worlds as Marvell would have it for several reasons, both legal and factual in nature. First, such a restrictive reading is contradictory to Federal Circuit precedent, which does not require a reasonable royalty to be tied only to use of the patented method (i.e., infringement). See, e.g., Lucent, 580 F.3d at 1334 ("A company licensing a patented method often has strong reasons not to tie the royalty amount strictly to usage."); cf. Hanson v. Alpine Valley Ski Area, Inc., 718 F.2d 1075, 1080-81 (Fed.Cir.1983) (upholding reasonable royalty based on availability of the method, rather than "actual use of the" invention). Further, one of the simplest ways to determine the value of an infringing use of a patented method during research is to ascertain how many sales were made based on that infringing use.
Second, taken in the context of the entire Mirror Worlds opinion, Judge Davis's holding actually undermines Marvell's argument because it is observes that Mirror Worlds should have based its infringement argument on the very same theory upon which CMU relies. "Mirror Worlds' infringement theory was based on Apple's sales, and Mirror Worlds did not present sufficient evidence to allow the jury to determine liability resulting from Apple's own use (direct infringement) of the methods." Mirror Worlds, 784 F.Supp.2d at 724 (emphasis added). Thus, Judge Davis was faced with a patent owner asserting infringement based on sales (which cannot infringe a method) and left with no evidence linking those sales to any infringement.
CMU's infringement theory, on the other hand, is based not on Marvell's sales, but on Marvell's own use (direct infringement) of the methods. Marvell has conceded the element of infringing use for purposes of the pending motions. Marvell has also conceded that its infringing use is the but-for cause of Marvell's sales. (See Docket No. 415 at ¶ 8). Thus, CMU has demonstrated that Marvell infringes the CMU Patents and that infringement is directly related to Marvell's sales. This evidence was lacking in the Mirror Worlds case.
As a final observation, the Court notes that Marvell relies heavily on the rule that U.S. patent laws are not to be applied extraterritorially. (See, e.g., Docket No. 357 at 3-7). The Court certainly agrees that this is the general rule. See Microsoft Corp. v. AT & T Corp., 550 U.S. 437, 454-55, 127 S.Ct. 1746, 167 L.Ed.2d 737 (2007) ("The presumption that United States law governs domestically but does not rule the world applies with particular force in patent law."). Given the posture of this case, however, Marvell's extraterritorial conduct argument is neutered by its admission that the parties dispute whether the actual sales of the Accused Chips took place in the United States or abroad. (See Docket No. 440 at 7). If the Court accepts CMU's position that these sales occurred within the United States, as it must at the summary judgment stage, see Enzo Biochem, 599 F.3d at 1338, then no part of the relevant conduct occurs outside the United States: Marvell's infringing use occurs here (Docket No. 357 at 1-2), and if the
The fact that Marvell infringes throughout the sales cycle establishes liability, and that liability is not affected by the Court's grant of summary judgment for non-infringement above. CMU has also provided sufficient evidence to demonstrate that Marvell's sales are tied to its own direct infringement during the sales cycle. As CMU's assertion that Marvell's sales may be used as a basis for calculating a reasonable royalty is justified, Marvell has failed to meet its burden at this stage of the case, Celotex, 477 U.S. at 325, 106 S.Ct. 2548, and summary judgment is inappropriate as to the damages portions of Marvell's motions. (Docket Nos. 356, 360).
For the foregoing reasons, the Court holds that Marvell's motions [356] and [360] are both GRANTED, in part, and DENIED, in part. The Court grants Marvell's extraterritorial conduct motion [356] insofar as Marvell cannot be found liable for direct or indirect infringement of any method claims of U.S. Patent Nos. 6,201,839 and 6,438,180 in connection with sales of chips that are never used in the United States. The Court denies that motion [356] with respect to such alleged damages arising from such sales, as the evidence of record, construed in favor of CMU, shows that such sales occur within the United States and they are the but-for result of Marvell's infringement of the CMU Patents during the sales cycle.
The Court also grants Marvell's licensed use motion [360] insofar as Marvell cannot be found liable for direct or indirect infringement of U.S. Patent Nos. 6,201,839 and 6,438,180 with respect to licensed use of the patented technology by non-party, Seagate Technology. The Court denies that motion [360] with respect to alleged damages arising from Marvell's sales to Seagate, as the evidence of record demonstrates that such sales occur within the United States and are the but-for result of Marvell's infringement of the CMU Patents during the sales cycle.
(Docket No. 398 at ¶ 11 (citing Docket No. 399-1, Ex. 5)).